Condition: Metastatic Breast Cancer · Sponsor: Sun Yat-sen University
The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: \- Does the heterogeneity of HER2 expression level and spatial distribution in different tissues affect the efficacy of trastuzumab deruxtecan in metastatic breast cancer?
This description comes directly from the study's public registry record.
Xiaoming Xie, MD, PhD · 86-020-87343806 · xiexm@sysucc.org.cn
Yutian Zou, MD, PhD · 86-020-87343806 · zouyt@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Dana-Farber Cancer Institute, Harvard Medical School | Boston, Massachusetts, United States | Recruiting |
| Fujian Cancer Hospital, Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The 10th Affiliated Hospital of Southern Medical University | Dongguan, Guangdong, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, Guangdong, China | Recruiting |
| The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. | Foshan, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Panyu Central Hospital, Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial Hospital of Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
| The Affiliated Cancer Hospital, Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangzhou University of Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06551220